Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulanermin in advanced NSCLC
NCT03083743Phase 3Unknown
- Sponsor
- Shanghai Gebaide Biotechnology Co., Ltd.
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of dulanermin in non-small cell lung cancer (NSCLC), sponsored by Shanghai Gebaide Biotechnology Co., Ltd.. Status: unknown.
02
Drugs
dulanermin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03083743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03083743.